Vaxcyte Statistics

Total Valuation

Vaxcyte has a market cap or net worth of $6.93 billion. The enterprise value is $5.89 billion.

Market Cap	6.93B
Enterprise Value	5.89B

Important Dates

The next estimated earnings date is Friday, May 10, 2024, after market close.

Earnings Date	May 10, 2024
Ex-Dividend Date	n/a

Share Statistics

Vaxcyte has 108.76 million shares outstanding. The number of shares has increased by 49.75% in one year.

Shares Outstanding	108.76M
Shares Change (YoY)	+49.75%
Shares Change (QoQ)	+0.84%
Owned by Insiders (%)	0.60%
Owned by Institutions (%)	96.52%
Float	99.24M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	5.60
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.54, with a Debt / Equity ratio of 0.02.

Current Ratio	7.54
Quick Ratio	n/a
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -32.00% and return on invested capital (ROIC) is -36.86%.

Return on Equity (ROE)	-32.00%
Return on Assets (ROA)	-29.70%
Return on Capital (ROIC)	-36.86%
Revenue Per Employee	n/a
Profits Per Employee	-$1.58M
Employee Count	254
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +31.31% in the last 52 weeks. The beta is 0.89, so Vaxcyte's price volatility has been lower than the market average.

Beta (1Y)	0.89
52-Week Price Change	+31.31%
50-Day Moving Average	67.30
200-Day Moving Average	57.82
Relative Strength Index (RSI)	49.99
Average Volume (30 Days)	778,957

Short Selling Information

The latest short interest is 8.24 million, so 7.58% of the outstanding shares have been sold short.

Short Interest	8.24M
Short Previous Month	8.26M
Short % of Shares Out	7.58%
Short % of Float	8.31%
Short Ratio (days to cover)	12.65

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-468.04M
Pretax Income	-402.27M
Net Income	-402.27M
EBITDA	-392.10M
EBIT	-402.27M
Earnings Per Share (EPS)	-$4.14

Full Income Statement

Balance Sheet

The company has $1.08 billion in cash and $29.22 million in debt, giving a net cash position of $1.05 billion or $9.66 per share.

Cash & Cash Equivalents	1.08B
Total Debt	29.22M
Net Cash	1.05B
Net Cash Per Share	$9.66
Equity / Book Value	1.24B
Book Value Per Share	11.41
Working Capital	950.62M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$296.79 million and capital expenditures -$67.88 million, giving a free cash flow of -$364.67 million.

Operating Cash Flow	-296.79M
Capital Expenditures	-67.88M
Free Cash Flow	-364.67M
FCF Per Share	-$3.75

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vaxcyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-49.75%
Shareholder Yield	-49.75%
Earnings Yield	-5.79%
FCF Yield	-5.25%

Dividend Details

Analyst Forecast

The average price target for Vaxcyte is $89.50, which is 40.48% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$89.50
Price Target Difference	40.48%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-4.85%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1